---
layout: default
title: Brigatinib
parent: 僅模型預測 (L5)
nav_order: 39
evidence_level: L5
indication_count: 10
---

# Brigatinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# BRIGATINIB: Evaluation Report — Insufficient Evidence Pack Data

## One-Sentence Summary

BRIGATINIB (DrugBank ID: DB12267) is a compound for which the current Evidence Pack contains **no original indication data**, **no TxGNN-predicted new indications**, and **no safety profile**.
A structured drug repurposing evaluation cannot be completed at this stage.
The drug is currently **not marketed in Germany**, and all downstream assessment steps are blocked until critical data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (No predictions or empirical studies in current pack) |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All five evaluation pillars — original indication, mechanism of action, TxGNN repurposing prediction, regulatory footprint, and safety profile — are either empty or blocked by unresolved data gaps. There is currently no valid repurposing hypothesis to assess, and the Blocking-severity safety gap (DG001) prevents entry into even the initial S1 safety screening step.

**To proceed, the following is needed:**

- **TxGNN prediction run** *(Critical)*: The `predicted_indications` array is empty. A complete TxGNN inference run against the disease knowledge graph must be executed before any repurposing opportunity can be identified or ranked.
- **Safety profile** *(Blocking — DG001)*: Package insert warnings and contraindications are absent. Download and parse the TFDA package insert PDF to unlock the S1 safety screening gate.
- **Mechanism of action** *(High — DG002)*: MOA data is unavailable. Retrieve pharmacological target and pathway information via DrugBank API (DB12267) to support mechanistic plausibility analysis.
- **Original indication data**: No approved indications are recorded in the pack. Cross-verify against TFDA, EMA, and DrugBank product listings to establish the clinical baseline.
- **Drug interaction data**: The DDI query returned zero results. Validate completeness via the DrugBank interaction database before assuming an absence of interactions.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

